Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Operations: 2018-2024

Historic Cash from Operations for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$67.6 million.

  • Silence Therapeutics' Cash from Operations rose 57.43% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year decrease of 15.79%. This contributed to the annual value of -$67.6 million for FY2024, which is 36.75% down from last year.
  • Per Silence Therapeutics' latest filing, its Cash from Operations stood at -$67.6 million for FY2024, which was down 36.75% from -$49.5 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Cash from Operations registered a high of $9.4 million during FY2021, and its lowest value of -$67.6 million during FY2024.
  • Its 3-year average for Cash from Operations is -$58.0 million, with a median of -$57.0 million in 2022.
  • Per our database at Business Quant, Silence Therapeutics' Cash from Operations plummeted by 903.30% in 2020 and then surged by 152.86% in 2021.
  • Silence Therapeutics' Cash from Operations (Yearly) stood at -$17.7 million in 2020, then soared by 152.86% to $9.4 million in 2021, then plummeted by 709.17% to -$57.0 million in 2022, then climbed by 13.29% to -$49.5 million in 2023, then slumped by 36.75% to -$67.6 million in 2024.